These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. Kawashima S; Joachim K; Abdelrahim M; Abudayyeh A; Jhaveri KD; Murakami N Korean J Transplant; 2022 Jun; 36(2):82-98. PubMed ID: 35919193 [TBL] [Abstract][Full Text] [Related]
28. Ocular and orbital side-effects of checkpoint inhibitors: a review article. Antoun J; Titah C; Cochereau I Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135 [TBL] [Abstract][Full Text] [Related]
29. Ocular surface complications following biological therapy for cancer. Ma KS; Tsai PF; Hsieh TY; Chodosh J Front Toxicol; 2023; 5():1137637. PubMed ID: 37424746 [TBL] [Abstract][Full Text] [Related]
30. Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. Calabrese LH; Caporali R; Blank CU; Kirk AD J Autoimmun; 2020 Dec; 115():102546. PubMed ID: 32980229 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Wang F; Wu X J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369 [TBL] [Abstract][Full Text] [Related]
32. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Wassmer CH; El Hajji S; Papazarkadas X; Compagnon P; Tabrizian P; Lacotte S; Toso C Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760542 [TBL] [Abstract][Full Text] [Related]
33. Determinants of Resistance to Checkpoint Inhibitors. Tran L; Theodorescu D Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080 [TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System. Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200 [TBL] [Abstract][Full Text] [Related]
35. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience. Fortes BH; Liou H; Dalvin LA Br J Ophthalmol; 2021 Sep; 105(9):1263-1271. PubMed ID: 32830124 [TBL] [Abstract][Full Text] [Related]
36. Ocular side effects of checkpoint inhibitors. Alba-Linero C; Alba E Surv Ophthalmol; 2021; 66(6):951-959. PubMed ID: 33440195 [TBL] [Abstract][Full Text] [Related]
37. Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. Nikita N; Banks J; Keith SW; Song A; Johnson JM; Wilson M; Sharma S; Lu-Yao G Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267602 [TBL] [Abstract][Full Text] [Related]
38. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637 [TBL] [Abstract][Full Text] [Related]
39. Multi-target combinatory strategy to overcome tumor immune escape. Yu Y Front Med; 2022 Apr; 16(2):208-215. PubMed ID: 35377102 [TBL] [Abstract][Full Text] [Related]